Vor Biopharma Inc. Payments to Acquire Marketable Securities
Vor Biopharma Inc. (VOR) reported Payments to Acquire Marketable Securities of $355.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-11
- Vor Biopharma Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $79.00M.
- Vor Biopharma Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $276.50M.
- Vor Biopharma Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $53.66M.
- Vor Biopharma Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $0.00.
- Vor Biopharma Inc. payments to acquire marketable securities for fiscal 2025 was $53.66M, a 441.25% increase from fiscal 2024.
- Vor Biopharma Inc. payments to acquire marketable securities for fiscal 2024 was $9.91M, a 86.77% decline from fiscal 2023.
- Vor Biopharma Inc. payments to acquire marketable securities for fiscal 2023 was $74.92M, a 39.18% decline from fiscal 2022.
- Vor Biopharma Inc. payments to acquire marketable securities for fiscal 2022 was $123.19M, a 40.38% increase from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $79.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $355.50M 10-Q · filed 2026-08-11 | $409.16M derived: sum of 3 quarters · filed 2026-08-11 | $409.16M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $276.50M 10-Q · filed 2026-05-13 | $330.16M derived: sum of 2 quarters · filed 2026-05-13 | $330.16M derived: sum of 3 quarters · filed 2026-05-13 | $330.16M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $53.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $53.66M derived: sum of 2 quarters · filed 2026-03-30 | $53.66M derived: sum of 3 quarters · filed 2026-08-11 | $53.66M 10-K · filed 2026-03-30 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-11 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-05-13 | $0.00 derived: sum of 3 quarters · filed 2026-05-13 | $1.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $1.00K derived: sum of 3 quarters · filed 2026-03-30 | $9.91M 10-K · filed 2026-03-30 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.00K derived: sum of 2 quarters · filed 2025-11-13 | $9.91M 10-Q · filed 2025-11-13 | $26.47M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $9.91M 10-Q · filed 2025-08-12 | $26.47M derived: sum of 3 quarters · filed 2025-08-12 | $26.47M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $9.91M 10-Q · filed 2025-05-14 | $26.47M derived: sum of 2 quarters · filed 2025-05-14 | $26.47M derived: sum of 3 quarters · filed 2025-05-14 | $61.43M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $16.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $16.55M derived: sum of 2 quarters · filed 2025-03-20 | $51.52M derived: sum of 3 quarters · filed 2025-03-20 | $74.92M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $34.96M derived: sum of 2 quarters · filed 2024-11-07 | $58.37M 10-Q · filed 2024-11-07 | $176.51M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $34.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $58.37M 10-Q · filed 2024-08-08 | $176.51M derived: sum of 3 quarters · filed 2024-08-08 | $176.51M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $23.41M 10-Q · filed 2024-05-09 | $141.55M derived: sum of 2 quarters · filed 2024-05-09 | $141.55M derived: sum of 3 quarters · filed 2024-05-09 | $141.55M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $118.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $118.14M derived: sum of 2 quarters · filed 2024-03-20 | $118.14M derived: sum of 3 quarters · filed 2024-03-20 | $123.19M 10-K · filed 2024-03-20 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $5.04M 10-Q · filed 2023-11-07 | $9.83M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $5.04M 10-Q · filed 2023-08-10 | $9.83M derived: sum of 3 quarters · filed 2023-08-10 | $17.68M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $5.04M 10-Q · filed 2023-05-11 | $9.83M derived: sum of 2 quarters · filed 2023-05-11 | $17.68M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $4.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $12.63M derived: sum of 2 quarters · filed 2023-03-23 | $87.76M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $7.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $82.97M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $75.12M 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |